Cidara Therapeutics Inc (CDTX)
20.40
+2.95
(+16.91%)
USD |
NASDAQ |
Nov 22, 16:00
21.31
+0.91
(+4.46%)
After-Hours: 20:00
Cidara Therapeutics Cash from Operations (Quarterly): -36.70M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -36.70M |
| June 30, 2024 | -103.78M |
| March 31, 2024 | -6.644M |
| December 31, 2023 | -12.72M |
| September 30, 2023 | -1.634M |
| June 30, 2023 | 2.822M |
| March 31, 2023 | -10.90M |
| December 31, 2022 | -21.00M |
| September 30, 2022 | 27.97M |
| June 30, 2022 | -11.84M |
| March 31, 2022 | -23.61M |
| December 31, 2021 | -14.91M |
| September 30, 2021 | -11.97M |
| June 30, 2021 | 3.44M |
| March 31, 2021 | -1.793M |
| December 31, 2020 | -11.13M |
| September 30, 2020 | -14.08M |
| June 30, 2020 | -14.07M |
| March 31, 2020 | -15.13M |
| December 31, 2019 | -15.20M |
| September 30, 2019 | 16.62M |
| June 30, 2019 | -12.81M |
| Date | Value |
|---|---|
| March 31, 2019 | -17.15M |
| December 31, 2018 | -13.67M |
| September 30, 2018 | -12.78M |
| June 30, 2018 | -15.53M |
| March 31, 2018 | -14.72M |
| December 31, 2017 | -9.491M |
| September 30, 2017 | -13.87M |
| June 30, 2017 | -12.03M |
| March 31, 2017 | -14.52M |
| December 31, 2016 | -11.73M |
| September 30, 2016 | -7.687M |
| June 30, 2016 | -9.472M |
| March 31, 2016 | -10.89M |
| December 31, 2015 | -6.738M |
| September 30, 2015 | -7.303M |
| June 30, 2015 | -5.866M |
| March 31, 2015 | -6.052M |
| December 31, 2014 | -3.172M |
| September 30, 2014 | -3.224M |
| June 30, 2014 | -0.904M |
| March 31, 2014 | -0.41M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-103.78M
Minimum
Jun 2024
27.97M
Maximum
Sep 2022
-14.64M
Average
-12.35M
Median
Cash from Operations (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 221.48M |
| Arbutus Biopharma Corp | -20.74M |
| GlycoMimetics Inc | -7.994M |
| FibroGen Inc | -8.376M |
| Cue Biopharma Inc | -7.527M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.106M |
| Cash from Financing (Quarterly) | -0.182M |
| Free Cash Flow | -160.15M |
| Free Cash Flow Per Share (Quarterly) | -5.636 |
| Free Cash Flow Yield | -155.8% |